Figure 1.

The original VA STARPORT study schema (a) and the current amended STARPORT study schema that includes de novo patients and up to 10 metastases (b). ADT = androgen deprivation therapy; CRPC = castration-resistant prostate cancer; rPFS = radiographic progression-free survival; cPFS = clinical progression-free survival; FFILP = freedom from local progression; MFS = metastasis-free survival; PCSS = prostate cancer-specific survival; OS = overall survival. * Includes any form of molecular PET/CT imaging for prostate cancer. ¥ Standard systemic therapy will be determined by the treating physician and must be consistent with current NCCN guidelines. It can be delivered by using: (1.) ADT or (2.) Enhanced system therapy delivered by combining ADT with any chemotherapy or androgen receptor axis targeted agent. £ Metastasis-directed therapy can be delivered with surgery or radiation, and those with local recurrence will be treated with local therapy per standard of care.